1179 related articles for article (PubMed ID: 22842228)
1. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
Krauthammer M; Kong Y; Ha BH; Evans P; Bacchiocchi A; McCusker JP; Cheng E; Davis MJ; Goh G; Choi M; Ariyan S; Narayan D; Dutton-Regester K; Capatana A; Holman EC; Bosenberg M; Sznol M; Kluger HM; Brash DE; Stern DF; Materin MA; Lo RS; Mane S; Ma S; Kidd KK; Hayward NK; Lifton RP; Schlessinger J; Boggon TJ; Halaban R
Nat Genet; 2012 Sep; 44(9):1006-14. PubMed ID: 22842228
[TBL] [Abstract][Full Text] [Related]
2. Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma.
Mar VJ; Wong SQ; Logan A; Nguyen T; Cebon J; Kelly JW; Wolfe R; Dobrovic A; McLean C; McArthur GA
Pigment Cell Melanoma Res; 2014 Nov; 27(6):1117-25. PubMed ID: 25043693
[TBL] [Abstract][Full Text] [Related]
3. Characterisation and outcome of RAC1 mutated melanoma.
Lodde GC; Jansen P; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Sucker A; Placke JM; Zaremba A; Albrecht LJ; Kowall B; Galetzka W; Becker JC; Tasdogan A; Zimmer L; Livingstone E; Hadaschik E; Schadendorf D; Ugurel S; Griewank K
Eur J Cancer; 2023 Apr; 183():1-10. PubMed ID: 36773463
[TBL] [Abstract][Full Text] [Related]
4. BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs.
Wong CW; Fan YS; Chan TL; Chan AS; Ho LC; Ma TK; Yuen ST; Leung SY;
J Clin Pathol; 2005 Jun; 58(6):640-4. PubMed ID: 15917418
[TBL] [Abstract][Full Text] [Related]
5. Mutational status of naevus-associated melanomas.
Shitara D; Tell-Martí G; Badenas C; Enokihara MM; Alós L; Larque AB; Michalany N; Puig-Butille JA; Carrera C; Malvehy J; Puig S; Bagatin E
Br J Dermatol; 2015 Sep; 173(3):671-80. PubMed ID: 25857817
[TBL] [Abstract][Full Text] [Related]
6. Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma.
Thomas NE; Edmiston SN; Alexander A; Millikan RC; Groben PA; Hao H; Tolbert D; Berwick M; Busam K; Begg CB; Mattingly D; Ollila DW; Tse CK; Hummer A; Lee-Taylor J; Conway K
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):991-7. PubMed ID: 17507627
[TBL] [Abstract][Full Text] [Related]
7. [ Spectrum of oncogene mutations is different in melanoma subtypes].
Mazurenko NN; Tsyganova IV; Lushnikova AA; Ponkratova DA; Anurova OA; Cheremushkin EA; Mikhailova IN; Demidov LV
Mol Biol (Mosk); 2015; 49(6):1022-9. PubMed ID: 26710785
[TBL] [Abstract][Full Text] [Related]
8. GAB2 amplifications refine molecular classification of melanoma.
Chernoff KA; Bordone L; Horst B; Simon K; Twadell W; Lee K; Cohen JA; Wang S; Silvers DN; Brunner G; Celebi JT
Clin Cancer Res; 2009 Jul; 15(13):4288-91. PubMed ID: 19509136
[TBL] [Abstract][Full Text] [Related]
9. Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis.
Hendricks WPD; Zismann V; Sivaprakasam K; Legendre C; Poorman K; Tembe W; Perdigones N; Kiefer J; Liang W; DeLuca V; Stark M; Ruhe A; Froman R; Duesbery NS; Washington M; Aldrich J; Neff MW; Huentelman MJ; Hayward N; Brown K; Thamm D; Post G; Khanna C; Davis B; Breen M; Sekulic A; Trent JM
PLoS Genet; 2018 Sep; 14(9):e1007589. PubMed ID: 30188888
[TBL] [Abstract][Full Text] [Related]
10. The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.
Watson IR; Li L; Cabeceiras PK; Mahdavi M; Gutschner T; Genovese G; Wang G; Fang Z; Tepper JM; Stemke-Hale K; Tsai KY; Davies MA; Mills GB; Chin L
Cancer Res; 2014 Sep; 74(17):4845-4852. PubMed ID: 25056119
[TBL] [Abstract][Full Text] [Related]
11. BRAF and NRAS mutations in melanoma and melanocytic nevi.
Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
Yaman B; Akalin T; Kandiloğlu G
Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
[TBL] [Abstract][Full Text] [Related]
13. A landscape of driver mutations in melanoma.
Hodis E; Watson IR; Kryukov GV; Arold ST; Imielinski M; Theurillat JP; Nickerson E; Auclair D; Li L; Place C; Dicara D; Ramos AH; Lawrence MS; Cibulskis K; Sivachenko A; Voet D; Saksena G; Stransky N; Onofrio RC; Winckler W; Ardlie K; Wagle N; Wargo J; Chong K; Morton DL; Stemke-Hale K; Chen G; Noble M; Meyerson M; Ladbury JE; Davies MA; Gershenwald JE; Wagner SN; Hoon DS; Schadendorf D; Lander ES; Gabriel SB; Getz G; Garraway LA; Chin L
Cell; 2012 Jul; 150(2):251-63. PubMed ID: 22817889
[TBL] [Abstract][Full Text] [Related]
14. Distinct sets of genetic alterations in melanoma.
Curtin JA; Fridlyand J; Kageshita T; Patel HN; Busam KJ; Kutzner H; Cho KH; Aiba S; Bröcker EB; LeBoit PE; Pinkel D; Bastian BC
N Engl J Med; 2005 Nov; 353(20):2135-47. PubMed ID: 16291983
[TBL] [Abstract][Full Text] [Related]
15. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.
Mar VJ; Wong SQ; Li J; Scolyer RA; McLean C; Papenfuss AT; Tothill RW; Kakavand H; Mann GJ; Thompson JF; Behren A; Cebon JS; Wolfe R; Kelly JW; Dobrovic A; McArthur GA
Clin Cancer Res; 2013 Sep; 19(17):4589-98. PubMed ID: 23833303
[TBL] [Abstract][Full Text] [Related]
16. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
[TBL] [Abstract][Full Text] [Related]
17. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.
Goel VK; Lazar AJ; Warneke CL; Redston MS; Haluska FG
J Invest Dermatol; 2006 Jan; 126(1):154-60. PubMed ID: 16417231
[TBL] [Abstract][Full Text] [Related]
18. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
[TBL] [Abstract][Full Text] [Related]
19. Analysis of SDHD promoter mutations in various types of melanoma.
Scholz SL; Horn S; Murali R; Möller I; Sucker A; Sondermann W; Stiller M; Schilling B; Livingstone E; Zimmer L; Reis H; Metz CH; Zeschnigk M; Paschen A; Steuhl KP; Schadendorf D; Westekemper H; Griewank KG
Oncotarget; 2015 Sep; 6(28):25868-82. PubMed ID: 26327518
[TBL] [Abstract][Full Text] [Related]
20. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
